Spontaneous adverse drug reaction reporting during the seasonal malaria chemoprevention campaign in 2022

[1]  S. Sirima,et al.  Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of P. falciparum Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa , 2022, Infection and drug resistance.

[2]  R. Abdulah,et al.  Clinical Manifestations and Genetic Influences in Sulfonamide-Induced Hypersensitivity , 2022, Drug, healthcare and patient safety.

[3]  J. Tarning,et al.  Pharmacokinetic considerations in seasonal malaria chemoprevention. , 2022, Trends in parasitology.

[4]  P. Walker,et al.  Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria , 2022, BMJ Global Health.

[5]  C. Plowe.  Malaria chemoprevention and drug resistance: a review of the literature and policy implications , 2022, Malaria journal.

[6]  J. Ouédraogo,et al.  Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study , 2021, Malaria journal.

[7]  A. Sommet,et al.  Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database , 2021, British journal of clinical pharmacology.

[8]  C. Ahanhanzo,et al.  Seeking research questions from implementers: considerations for leveraging ground actors research needs in the fight against malaria in West Africa , 2020, Malaria journal.

[9]  A. Dicko,et al.  Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study , 2020, The Lancet.

[10]  N. Irrera,et al.  A 7-Years Active Pharmacovigilance Study of Adverse Drug Reactions Causing Children Admission to a Pediatric Emergency Department in Sicily , 2020, Frontiers in Pharmacology.

[11]  S. Balogun,et al.  Impacts of Seasonal Malaria Chemoprevention on Malaria Burden among under Five-Year-Old Children in Borno State, Nigeria , 2020, Journal of tropical medicine.

[12]  Ruchi Srivastava,et al.  Pattern of adverse drug reactions occurring at department of neurology of a tertiary care hospital in India , 2020 .

[13]  R. Adisa,et al.  Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria , 2019, BMC Health Services Research.

[14]  J. Foushee,et al.  Sulfonamide Allergies , 2019, Pharmacy.

[15]  Justin M. Cohen,et al.  Seasonal malaria chemoprevention packaged with malnutrition prevention in northern Nigeria: A pragmatic trial (SMAMP study) with nested case-control , 2019, PloS one.

[16]  J. Ndiaye,et al.  Evaluation of Two Strategies for Community-Based Safety Monitoring during Seasonal Malaria Chemoprevention Campaigns in Senegal, Compared with the National Spontaneous Reporting System , 2018, Pharmaceutical Medicine.

[17]  M. Bangs,et al.  Severe Allergic Reaction to Oral Artesunate-Amodiaquine Combination Treatment for Malaria: Case Report in the Democratic Republic of Congo , 2017 .

[18]  M. Rieder,et al.  Adverse Drug Reactions in Children: The Double‐Edged Sword of Therapeutics , 2017, Clinical pharmacology and therapeutics.

[19]  Afonso Cavaco,et al.  The value of patient reporting to the pharmacovigilance system: a systematic review , 2017, British journal of clinical pharmacology.

[20]  H. Rees,et al.  Pharmacovigilance: A public health priority for South Africa. , 2017, South African health review.

[21]  B. Cissé,et al.  Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial , 2016, PloS one.

[22]  C. Curtain,et al.  Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors , 2016, Drug Safety.

[23]  A. Ali,et al.  Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions , 2015, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[24]  J. Coleman,et al.  Adverse drug reactions. , 2016, Clinical medicine.

[25]  A. Onoja,et al.  Self-reported sulphonamide hypersensitivity reactions in adults living in Ibadan, Nigeria: A cross-sectional, community-based study , 2015, Nigerian medical journal : journal of the Nigeria Medical Association.

[26]  Hong Jiang,et al.  Adverse Drug Reactions of Spontaneous Reports in Shanghai Pediatric Population , 2014, PloS one.

[27]  I. Oreagba,et al.  Impact of training on Nigerian healthcare professionals' knowledge and practice of pharmacovigilance. , 2013, The International journal of risk & safety in medicine.

[28]  V. Adabayeri,et al.  Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis. , 2012, Ghana medical journal.

[29]  M. Bonati,et al.  Active surveillance of adverse drug reactions in children in five Italian paediatric wards , 2012 .

[30]  J. Kendrick,et al.  Vomiting of oral medications by pediatric patients: survey of medication redosing practices. , 2012, The Canadian journal of hospital pharmacy.

[31]  Su Golder,et al.  Adverse Drug Reactions in Children—A Systematic Review , 2012, PloS one.

[32]  C. Adithan,et al.  A study of adverse drug reactions in pediatric patients , 2011, Journal of pharmacology & pharmacotherapeutics.

[33]  A. O. Afolabi,et al.  Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting among Healthcare Workers in a Tertiary Centre in Northern Nigeria , 2011 .

[34]  P. Schulz,et al.  Assessing the benefit:risk ratio of a drug - randomized and naturalistic evidence , 2011, Dialogues in clinical neuroscience.

[35]  L. French,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome , 2010, Orphanet journal of rare diseases.

[36]  O. Gaye,et al.  Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[37]  K. Oshikoya,et al.  Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria , 2009, BMC clinical pharmacology.

[38]  K. Allen.  The vomiting child--what to do and when to consult. , 2007, Australian family physician.

[39]  Tony Nunn,et al.  Formulation of medicines for children. , 2005, British journal of clinical pharmacology.

[40]  C. Slatore,et al.  Sulfonamide hypersensitivity. , 2004, Immunology and allergy clinics of North America.

[41]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[42]  R. Wittes.  Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature. , 1987, Canadian family physician Medecin de famille canadien.

[43]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[44]  H. Kolb,et al.  THE EFFECT OF A SYNTHETIC ANTIMALARIAL (AMODIAQUINE) ON THE RETINA. , 1964, The British journal of dermatology.

[45]  Swati Mishra,et al.  Monitoring of Adverse Drug Reactions in Pediatric Department of a Tertiary Care Teaching Hospital : A Hospital Based Observational Study , 2022 .